Immunostimulating reconstituted influenza virosomes

Vaccine

Volumn 21, Issue 9-10, 2003, Pages 921-924

  Zurbriggen, Rinaldo ^a  

^a Pevion Biotech Ltd   (Switzerland)

Author keywords

Immune response; IRIVs; Liposomal

Indexed keywords

ALUMINUM HYDROXIDE; ANTIGEN; BACTERIAL TOXIN; DEOXYRIBONUCLEASE; DEOXYRIBONUCLEOPROTEIN; DIPHTHERIA VACCINE; HEPATITIS A VACCINE; IMMUNOLIPOSOME; IMMUNOSTIMULATING AGENT; IMMUNOSTIMULATING RECONSTITUTED INFLUENZA VIROSOME; INFLUENZA VACCINE; MULTIPLE ANTIGEN PEPTIDE; RIBONUCLEASE; STREPTAVIDIN; TETANUS TOXOID; UNCLASSIFIED DRUG; VIROSOME;

ANTIBODY PRODUCTION; B LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; DIPHTHERIA; DRUG TARGETING; HEPATITIS A; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; LICENSING; LIPID BILAYER; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TETANUS; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; B-LYMPHOCYTES; HUMANS; INFLUENZA VACCINES; LIPOSOMES; MICROSCOPY, ELECTRON; T-LYMPHOCYTES; VIROSOMES;

EID: 0037435877     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00541-8     Document Type: Conference Paper

References (21)

1. Abrosch F, Glück R, Herzog C. Clinical and immunological studies with a new virosome-based hepatitis A vaccine. In: Proceeding of 2nd European Congress on Tropical Medicines, Liverpool; 1998.
2. Holzer B.R., Hatz C., Schmid-Sissolak D., Glück R., Althaus B., Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine. 14:1996;982-986.
3. Bevier P, Farinelli T, Loutan L, Herzog C, Glück R. Long-term immunogenicity following immunization with a virosome hepatitis A vaccine. Abstracts of 5th International Conference on Travel Medicines, Geneva; 1997 [abstract no. 127].
4. Mayorga O, Egger M, Zellmeyer M, Glück R, Herzog C, Frösner G. Efficacy of a virosome formulated hepatitis A vaccine in an endemic region in Nicaragua: a randomized plazebo-controlled trial. Abstract of 37th ICAAC, Toronto; 1997 [abstract no. H-4].
5. Conne P., Gauthey L., Vernet P., Althaus B., Que J.U., Finkel B.et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine. 15:1997;1675-1679.
6. Cryz S.J., Que J.U., Glück R. A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Vaccine. 14:1996;1381-1383.
7. 2 amino-terminal fusion peptide but not the coiled coil region. J. Biol. Chem. 271:1996;13417-13421.
8. 2-terminal segment during influenza virus-induced membrane fusion. J. Biol. Chem. 267(28):1992;20225-20232.
9. Matlin K.S., Reggio H., Helenius A., Simmons K. Infections entry pathway of influenza virus in a canine kidney cell line. J. Cell. Biol. 91:1981;601-613.
10. Glück R. Liposomal presentation of antigens for human vaccines. In: Powell MR, Newman MJ, editors. Vaccine design. New York: Plenum Press; 1995. p. 325-45.
11. Zurbriggen R., Novak-Hofer I., Seelig A., Glück R. IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Prog. Lipid Res. 39(1):2000;3-18.
12. Zurbriggen R., Glück R. Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine. 17:1999;1301-1305.
13. Glück U., Gebbers J.O., Glück R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J. Virol. 73(9):1999;7780-7786.
14. Moreno R., Jiang L., Moehle K., Zurbriggen R., Glück R., Robinson J.A.et al. Exploiting conformationally constrained peptidomimetics and an efficient human compatible delivery system in synthetic vaccine design. Chem. Biol. Chem. 2:2002;834-838.
15. Zinkernagel R.M., Callahan G.N., Althage A., Cooper S., Streilein J.W., Klein J. The lymphoreticular system in triggering virus plus self-specific cytotoxic T cells: evidence for T help. J. Exp. Med. 147:1978;897-911.
16. Keene J.A., Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155:1982;768-782.
17. Bennett S.R., Carbone F.R., Karamalis F., Miller J.F., Heath W.H. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T-cell help. J. Exp. Med. 186:1997;65-70.
18. Toes R.E., Ossendorp F., Offringa R., Melief C.J. CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189:1999;753-756.
19. Arkema A., Huckriede A., Schoen P., Wilschut J., Daemen T. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine. 18(14):2000;1327-1333.
20. Cusi M.G., Zurbriggen R., Valassina M., Bianchi S., Durrer P., Valensin P.E.et al. Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity. Virology. 277(1):2000;111-118.
21. Waelti E., Wegmann N., Schwaninger R., Wetterwald A., Wingenfeld C., Rothen-Rutishauser B.et al. Targeting her-2/neu with antirat Neu virosomes for cancer therapy. Cancer Res. 62(2):2002;437-444.